Introduction {#s1}
============

Glucagon, a 29-amino acid-long hormone synthetized in pancreatic α-cells through cleavage of its precursor, proglucagon, by prohormone convertase 2 (PC2), counterbalances the effects of insulin on blood glucose homeostasis by stimulating hepatic glycogenolysis and gluconeogenesis ([@bib13]). In addition, the two hormones act in a paracrine fashion to reciprocally regulate α- and β-cell function ([@bib43]).

Hypersecretion of glucagon in diabetes exacerbates hepatic glucose output, thereby fostering hyperglycemia and ketogenesis ([@bib41]; [@bib42]; [@bib34]; [@bib8]). In consequence, antagonists of glucagon signaling are currently being tested in clinical trials for diabetes ([@bib3]). The importance of glucagon signaling in diabetes was recently highlighted in studies performed with glucagon receptor knockout (*Gcgr^-/-^*) mice and in animals lacking α-cells due to pancreatic aristaless-related homeobox (*Arx*) deficiency. Surprisingly, these animals did not exhibit the usual signs of diabetes, such as hyperglycemia or glucose intolerance, after streptozotocin (STZ)-mediated β-cell destruction ([@bib7]; [@bib22]; [@bib23]; [@bib17]). These findings lead to hypothesize that glucagon is responsible for the features of diabetes ([@bib44]). Although suppression of glucagon action is likely to attenuate the consequences of insulin deficiency, its primary role in the hyperglycemia is uncertain. Indeed, because STZ causes an incomplete β-cell ablation due to variations in administration protocols and in genetic background-dependent sensitivity ([@bib9]; [@bib4]; [@bib16]), it is possible that the "diabetes resistance" phenotype of *Gcgr^-/-^* mice relies on the action of insulin from residual β-cells. Thus, to determine whether lack of glucagon signaling would also prevent hyperglycemia and diabetes in the context of a more severe insulin deficiency, we used a transgenic model of diphtheria toxin (DT)-mediated β-cell ablation, termed *RIP-DTR*, which leads to an almost complete β-cell elimination ([@bib40]; [@bib6]). Also, because adult *RIP-DTR* mice spontaneously reconstitute new insulin-producing cells by α-cell transdifferentiation in this condition of severe insulin insufficiency, we explored whether the compensatory α-cell hyperplasia due to glucagon signaling blockade ([@bib11]; [@bib12]; [@bib25]) influences the reprogramming of α-cells toward insulin production.

Here we show that near-total β-cell loss triggers severe hyperglycemia and all the metabolic features of type 1 diabetes (cachexia, glucose intolerance, and death) in mice with constitutive or induced glucagon signaling deficiency. We report that the absence of hyperglycemia observed in glucagon-deficient mice after STZ treatment can be explained through the persistence of a residual β-cell mass, which ensures a low level of insulin action.

Results {#s2}
=======

Near-total β-cell ablation leads to full-blown diabetes in mice lacking glucagon signaling {#s2-1}
------------------------------------------------------------------------------------------

Recent reports indicate that *Gcgr^-/-^* mice do not develop hyperglycemia after STZ-mediated β-cell loss. Here we aimed at determining the effect of the absence of glucagon action in the context of a more extreme insulin deficiency. For this purpose, we crossed *Gcgr^-/-^* mutant animals ([@bib12]) with *RIP-DTR* mice, in which diphtheria toxin (DT) injection triggers the near-total (\>99% ) β-cell loss ([@bib40]).

*RIP-DTR;Gcgr^-/-^* mice, like *Gcgr^-/-^* mice, displayed lower basal glucose levels than controls *(RIP-DTR;Gcgr^+/+^* and *RIP-DTR;Gcgr^+/-^*; not shown) ([@bib12]). Upon DT-induced β-cell ablation, both control and knockout animals developed severe hyperglycemia, with a slower kinetics in *RIP-DTR;Gcgr^-/-^* mice ([Figure 1A](#fig1){ref-type="fig"}). Animals of both groups lost weight at similar rates ([Figure 1B](#fig1){ref-type="fig"}), and died in absence of exogenous insulin treatment ([Figure 1C](#fig1){ref-type="fig"}). By contrast, administration of long-acting insulin, although insufficient to normalize blood glucose levels, permitted survival and body weight maintenance ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). As soon as insulin treatment was discontinued, blood glucose levels and body weight quickly deteriorated in all groups. Altogether, these findings indicate that *Gcgr^-/-^* mice are not protected against hyperglycemia after near-total β-cell loss, but develop classical signs of type 1 diabetes and require insulin therapy.10.7554/eLife.13828.003Figure 1.*Gcgr^-/-^* mice become diabetic after massive β-cell ablation.(**A**) Random-fed glycemia (*left*) and area under the glycemia curve (AUC) between days 0 and 7 after DT (*right*) in untreated (Untr.) and DT-treated *RIP-DTR;Gcgr^+/-^* and *RIP-DTR;Gcgr^-/-^* females. (**B**) Body weight (*left*) and AUC body weight (days 0--7 after DT; *right*). **†**, all mice of the group were dead at this time point (see [Figure 1C](#fig1){ref-type="fig"}). \*p\<0.05; \*\*p\<0.01; Mann-Whitney *U* test. *C*: Survival curve of *RIP-DTR;Gcgr^+/-^* and *RIP-DTR;Gcgr^-/-^* mice after DT treatment (N=5--6). Survival analysis of DT-treated animals (*Gcgr^+/-^* versus *Gcgr^-/-^):* p=0.044; Log-rank test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.003](10.7554/eLife.13828.003)10.7554/eLife.13828.004Figure 1---figure supplement 1.Insulin administration stabilizes body weight and allows survival of DT-treated *Gcgr^-/-^*mice.Glycemia (*left*) and body weight (*right*) of *RIP-DTR;Gcgr^+/+^* (blue triangles, N=7), *RIP-DTR;Gcgr^+/-^* (black squares, N=9), and *RIP-DTR;Gcgr^-/-^* (red circles, N=9) males following DT-mediated β-cell ablation and exogenous insulin treatment. Grey areas indicate the period during which mice were treated with insulin detemir (5 U/kg/day between days 6 and 25).**DOI:** [http://dx.doi.org/10.7554/eLife.13828.004](10.7554/eLife.13828.004)

Constitutive *Gcgr* deletion leads to increased embryonic lethality, and defects in pancreatic development and islet-cell maturation ([@bib46]; [@bib47]; [@bib30]). Since these abnormalities may encompass long-lasting compensatory metabolic adaptations, we conditionally inhibited glucagon action in adult mice that had developed normally using a glucagon receptor antagonizing monoclonal antibody (anti-GCGR mAb). We first assessed its activity in C57BL/6 wild type mice ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In agreement with a previously described antibody ([@bib14]; [@bib50]), anti-GCGR treatment led to a reduction in basal glycemia ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), and triggered α-cell hyperplasia and hypertrophy, as observed in *Gcgr^-/-^* animals ([Figure 2---figure supplement 1C--D](#fig2s1){ref-type="fig"}) ([@bib12]). In addition, antibody-treated *Gcgr^+/+^* mice showed altered responses, like *Gcgr^-/-^* animals, to intraperitoneal glucose and insulin tolerance tests ([Figure 2---figure supplement 1E--F](#fig2s1){ref-type="fig"}). Anti-GCGR administration in *Gcgr^+/+^* mice therefore phenocopies the main metabolic and cellular alterations of *Gcgr^-/-^* mice and thus represents a valuable tool for inducing glucagon signaling antagonism in vivo.

To assess whether induced glucagon receptor blockade prevents diabetes upon near-total β-cell ablation, we pre-treated adult *RIP-DTR* mice with the anti-GCGR mAb for 3 weeks, and then injected them with DT ([Figure 2A](#fig2){ref-type="fig"}). In agreement with the above results using *RIP-DTR;Gcgr^-/-^* animals, all mice became severely hyperglycemic and lost weight after DT, regardless of antibody treatment ([Figure 2B--C](#fig2){ref-type="fig"}). Moreover, only insulin administration allowed for survival following β-cell ablation, not glucagon receptor inhibition ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Collectively, these observations indicate that the lack of glucagon signaling is not sufficient per se to prevent severe hyperglycemia and diabetes following extreme β-cell loss, and contrast with previous studies in which *Gcgr^-/-^*, or anti-GCGR-treated mice did not develop the metabolic manifestations of the disease when β-cell ablation was mediated by STZ ([@bib7]; [@bib22]; [@bib23]; [@bib49]).10.7554/eLife.13828.005Figure 2.Anti-GCGR mAb-treated mice become diabetic after massive β-cell ablation.(**A**) Experimental design. (**B-C**) Random-fed glycemia (**B**) and body weight (**C**) after DT in C57BL/6 males pre-treated with vehicle or mAb (N=3).**DOI:** [http://dx.doi.org/10.7554/eLife.13828.005](10.7554/eLife.13828.005)10.7554/eLife.13828.006Figure 2---figure supplement 1.Anti-GCGR mAb administration recapitulates the metabolic and cellular phenotypes of *Gcgr^-/-^* mice.(**A**) Experimental design. 9 mg/kg anti-GCGR mAb was injected i.p. 3 times per week for 3 weeks in C57BL/6 animals. (**B**) *Left:* Random fed glycemia of vehicle- (black squares) or mAb-treated males (red triangles). The grey area indicates the period of antibody treatment. *Right:* Area under the glycemia curves. \*p\<0.05; Mann-Whitney *U* test. **C** and **D**. Confocal images of pancreatic islet sections from vehicle- (**C**) and mAb-treated (**D**) males. α-cell hyperplasia and hypertrophy (compare **C'** and **D'**, the dashed lines represent the cell perimeters) are observed in islets from mAb-treated mice. Scale bars: 20 μm. **E** and **F**. Intraperitoneal glucose tolerance test (**E**) and insulin tolerance test (**F**) performed in *Gcgr^+/+^* (black squares, N=9), *Gcgr^-/-^* (grey circles, N=10), and mAb pre-treated *Gcgr^+/+^* (red triangles, N=10) males. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; *Gcgr^+/+^* versus mAb-treated *Gcgr^+/+^* mice. †, p\<0.05; ††, p\<0.01; †††, p\<0.001; *Gcgr^+/+^* versus *Gcgr^-/-^* mice; two-way ANOVA. The difference between *Gcgr^-/-^* and mAb-treated *Gcgr^+/+^* mice is not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.006](10.7554/eLife.13828.006)10.7554/eLife.13828.007Figure 2---figure supplement 2.Insulin administration is required to stabilize body weight and allow survival of anti-GCGR-treated mice after DT.(**A-C**) Exogenous insulin, but not anti-GCGR mAb treatment, stabilizes body weight and improves survival after extreme β-cell loss. (**A**) Experimental design. (**B**) Evolution of body weight following DT administration in *RIP-DTR* males treated with anti-GCGR mAb and/or exogenous insulin (N=5--12). (**C**) Survival curves. Survival analyses are indicated next to the legend: n.s., not significant; \*\*p\<0.01; \*\*\*p\<0.001; Log-rank test. Insulin was administered as subcutaneous implants (antibody-untreated mice), or as injections of long-acting insulin (antibody-treated mice) because insulin implants lead to hypoglycemia and death in mice with deficient glucagon signaling.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.007](10.7554/eLife.13828.007)

DT leads to a more complete β-cell ablation than STZ {#s2-2}
----------------------------------------------------

The different impact of STZ and DT treatments on glycemia in *Gcgr^-/-^* mice may result from a difference in completeness of β-cell destruction. To test this hypothesis, we compared the relative ablation efficiencies of these two methods. To maximize β-cell destruction, we treated *Gcgr^+/-^* and *Gcgr^-/-^* mice with two high doses of STZ (200 and 150 mg/kg, one week apart). Following the first injection, control mice became severely hyperglycemic. By contrast, *Gcgr^-/-^* animals remained normoglycemic even after the second STZ injection, as previously reported (not shown) ([@bib22]; [@bib23]). *RIP-DTR;Gcgr^-/-^* animals remained markedly hyperglucagonemic after STZ- or DT-mediated β-cell loss and α-cell mass was not affected ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). Histologically, we observed that nearly 90% of islet sections were totally devoid of β-cells after DT, versus only 45% after STZ ([Figure 3A](#fig3){ref-type="fig"}). Accordingly, the β-cell mass and pancreatic insulin content were reduced by 98--99% after DT, but only by 70--80% after STZ ([Figure 3B--C](#fig3){ref-type="fig"}). In addition, plasma insulin levels were just above detection threshold after DT, but readily detectable after STZ ([Figure 3D](#fig3){ref-type="fig"}). We made similar observations in mice with normal glucagon signaling ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Together, these results indicate that β-cell destruction is more complete after DT- than after STZ-treatment in *Gcgr^-/-^* mice.10.7554/eLife.13828.008Figure 3.DT administration leads to a more complete β-cell ablation than STZ.(**A**) Islet sections stained for insulin (red) and glucagon (green) from untreated, STZ-, or DT-treated *RIP-DTR;Gcgr^-/-^* females, 6 days after the last STZ or DT injection. Scale bars: 20 μm. (**B-D**) β-cell mass (**B**), pancreatic insulin content (**C**) and fed plasma insulin levels (**D**) in untreated (Untr.), STZ-, or DT-treated *RIP-DTR;Gcgr^-/-^* males and females, 6 days after the last injection. STZ administration: two injections (200 and 150 mg/kg). \*p\<0.05; \*\*p\<0.01; Mann-Whitney *U* test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.008](10.7554/eLife.13828.008)10.7554/eLife.13828.009Figure 3---figure supplement 1.*RIP-DTR;Gcgr^-/-^* mice remain hyperglucagonemic and α-cell mass is not affected after STZ- or DT-treatment.(**A-B**) fed plasma glucagon levels (**A**) and α-cell mass (**B**) in untreated (Untr.), STZ-, or DT-treated *RIP-DTR;Gcgr^+/-^* and *RIP-DTR;Gcgr^-/-^* males and females, measured 6 days after the last injection. STZ administration: two injections (200 and 150 mg/kg). \*\*p\<0.01; Mann-Whitney *U* test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.009](10.7554/eLife.13828.009)10.7554/eLife.13828.010Figure 3---figure supplement 2.Higher efficiency of β-cell ablation after DT- than after STZ-treatment in mice with normal glucagon signaling.(**A-B**) β-cell mass (**A**) and pancreatic insulin content (**B**) in untreated (Untr.), STZ-, or DT-treated *RIP-DTR;Gcgr^+/-^* females, measured 6 days after the last injection. STZ administration: two injections (200 and 150 mg/kg). \*\*p\<0.01; Mann-Whitney *U* test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.010](10.7554/eLife.13828.010)

Residual insulin action protects STZ-treated *Gcgr^-/-^* mice from hyperglycemia {#s2-3}
--------------------------------------------------------------------------------

Because β-cell ablation was incomplete after STZ, we aimed at determining whether the action of residual circulating insulin might, in combination with glucagon signaling deficiency, protect *Gcgr^-/-^* mice from diabetes.

To test this hypothesis, we inhibited insulin action using the insulin receptor antagonist drug S961 ([@bib33]). In vivo, S961 administration induces hyperglycemia in wild type animals and closely recapitulates the phenotype of mice with liver-specific insulin receptor deletion ([@bib52]; [@bib27]). In agreement with its previously reported action, S961 administration in *Gcgr^+/-^* mice triggered a strong increase in glycemia ([Figure 4A](#fig4){ref-type="fig"}; blue dashed vs black continuous line). Interestingly, *Gcgr^-/-^* animals exhibited a smaller but significant increase in glycemia, indicating that glucagon deficiency has a beneficial effect in this situation of relative insulin deficit (purple dashed vs red continuous line). Although STZ-treated *Gcgr*^-/-^ mice remained normoglycemic, as previously reported ([@bib7]; [@bib22]; [@bib23]), they developed severe hyperglycemia after insulin receptor inhibition (continuous vs dotted purple line). This suggests that residual insulin action, likely originating from STZ-escaping β-cells, is still present after STZ administration in *Gcgr^-/-^* animals, and is necessary to prevent hyperglycemia and diabetes.10.7554/eLife.13828.011Figure 4.Inhibition of insulin action triggers hyperglycemia in STZ-treated *Gcgr^-/-^*mice.(**A**) Random-fed glycemia after STZ and/or S961 administration in *Gcgr^+/-^* and *Gcgr^-/-^* females (left), and area under the glycemia curve (AUC) during S961 treatment (right). (**B-D**) Hepatic Pepck (top) and Glucokinase (bottom) mRNA levels relative to those of untreated *Gcgr^+/-^* (control) mice (N=4--6). (**B**) Glucagon deficiency: *Gcgr^-/-^* background. (**C**) Insulin deficiency: β-cell ablation or insulin signaling inhibition. (**D**) Combined deficiency: β-cell ablation and/or insulin signaling inhibition in a *Gcgr^-/-^* background. (**E-G**) FoxO1 mRNA levels in skeletal muscle, relative to those of untreated *Gcgr^+/-^* mice (N=4--6). STZ administration: 200 mg/kg at day 0 and 150 mg/kg at day 7. S961 treatment: osmotic pump (days 15 to 21). \*p\<0.05; \*\*p\<0.01; Mann-Whitney *U* test. Only groups that exhibited a \> twofold regulation as compared to controls (dashed lines) were tested.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.011](10.7554/eLife.13828.011)10.7554/eLife.13828.012Figure 4---figure supplement 1.Higher hepatic PEPCK protein expression after DT in both *Gcgr^+/-^* and *Gcgr^-/-^* mice.Western blot analysis showing PEPCK and Tubulin expression in the liver of untreated (untr.) and DT-treated *RIP-DTR-Gcgr+/-* and *RIP-DTR-Gcgr-/-* females (left). Quantification of PEPCK band intensities relative to Tubulin is shown on the right.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.012](10.7554/eLife.13828.012)10.7554/eLife.13828.013Figure 4---figure supplement 2.Liver glycogen concentration is reduced after DT-treatment in both *RIP-DTR-Gcgr^+/-^* and *RIP-DTR-Gcgr^-/-^* mice.Liver glycogen concentration in different conditions of insulin and/or glucagon deficiency (N=4). \*p\<0.05; Mann-Whitney *U* test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.013](10.7554/eLife.13828.013)10.7554/eLife.13828.014Figure 4---figure supplement 3.Expression of genes negatively regulated by insulin signaling in skeletal muscle.mRNA levels of genes inhibited by insulin in skeletal muscle (gastrocnemius), relative to those of untreated *Gcgr^+/-^* females (normalized to *Actb, Gapdh*, and *Gusb*) (N=4--6). Irs2, Insulin receptor substrate 2; Fbxo32, F-box only protein 32 (Atrogin-1); Trim63, Tripartite motif-containing 63 (MuRF1); 4e-bp1, Eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1); Gadd45a, Growth arrest and DNA-damage-inducible 45 alpha; p21, Cyclin-dependent kinase inhibitor 1A (Cdkn1a). p27, Cyclin-dependent kinase inhibitor 1B (Cdkn1b). \*p\<0.05; \*\*p\<0.01; Mann-Whitney *U* test. Only groups that exhibited a \> twofold regulation as compared to controls (dashed lines) were tested.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.014](10.7554/eLife.13828.014)

To better characterize the effect of insulin insufficiency in a glucagon-deficient context, we evaluated hepatic transcript levels of Phosphoenolpyruvate carboxykinase (Pepck) and Glucokinase (Gck), two hormone-sensitive enzymes whose transcription is regulated by the relative levels of glucagon and insulin signaling ([@bib32]; [@bib5]; [@bib18]). Liver is a relevant organ to assess the impact of insulin and glucagon deficiency because re-expression of the glucagon receptor in the liver of STZ-treated *Gcgr^-/-^* mice, and conditional inactivation of the insulin receptor in hepatocytes are both sufficient to trigger hyperglycemia ([@bib23]; [@bib27]). In conditions of glucagon deficiency (increased insulin/glucagon ratio; *Gcgr*^-/-^ mice), we observed a decreased expression of the gluconeogenic enzyme Pepck and an increased expression of the glycolytic enzyme Gck as compared to *Gcgr^+/-^* controls ([Figure 4B](#fig4){ref-type="fig"}), which is consistent with a previous study ([@bib51]). By contrast, upon induced insulin deficiency (decreased insulin/glucagon ratio), as in STZ-, S961-, or DT-treated Gcgr^+/-^ animals, Pepck and Gck exhibited the opposite regulation ([Figure 4C](#fig4){ref-type="fig"}). We observed the strongest effect after DT, which caused a 1000-fold decrease in Gck expression, suggesting that it led to a more complete suppression of insulin action than STZ or S961. When inducing insulin insufficiency in a *Gcgr^-/-^* background, a situation of combined insulin and glucagon deficiency, we observed Pepck and Gck mRNA levels similar to those measured in untreated *Gcgr^+/-^* control mice, except after DT, which induced a strong downregulation of Gck expression in *Gcgr^-/-^* livers ([Figure 4D](#fig4){ref-type="fig"}). We also confirmed the increase in hepatic PEPCK expression after DT at the protein level ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Similarly, DT-, but not STZ-treatment depleted liver glycogen stores in *RIP-DTR;Gcgr^-/-^* animals ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). These results suggest that lack of glucagon action can compensate for the effect of partial insulin insufficiency on the expression of rate-limiting enzymes and hepatic glycogen metabolism, but not after near-total β-cell loss, a situation where the effect of insulin deficiency outweighs that of glucagon deficiency.

We then assessed insulin signaling activity in skeletal muscle by measuring the expression of the transcription factor Forkhead box protein O1 (FoxO1) and of several of its target genes, such as Insulin receptor substrate 2 (Irs2), which are induced upon insulin insufficiency ([@bib24]). FoxO1 mRNA levels were similar in untreated *Gcgr^+/-^* and *Gcgr^-/-^* mice ([Figure 4E](#fig4){ref-type="fig"}). In *Gcgr^-/-^* animals, STZ or S961 administration did not significantly affect FoxO1 expression. By contrast, FoxO1 and its targets were strongly upregulated upon combined STZ and S961-, or DT-treatment, reflecting a more severe insulin insufficiency ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

Together, these results indicate that lack of glucagon signaling efficiently compensates for the consequences of insulin insufficiency only if residual insulin action persists after β-cell loss.

Glucagon signaling blockade attenuates hyperglycemia after STZ-mediated β-cell loss only when residual insulin production persists {#s2-4}
----------------------------------------------------------------------------------------------------------------------------------

As *Gcgr^-/-^* mice exhibit resistance to STZ-induced hyperglycemia, we assessed the impact of glucagon signaling blockade on C57BL/6 mice made hyperglycemic with a single injection of either 175 or 225 mg/kg STZ. Once the animals were hyperglycemic, we implanted them with an osmotic pump containing the anti-GCGR mAb. In mice injected with 175 mg/kg STZ, antibody treatment strongly reduced, but did not completely normalize, blood glucose levels ([Figure 5A and B](#fig5){ref-type="fig"}). By contrast, animals that had received 225 mg/kg STZ remained severely hyperglycemic (\>30 mM) after anti-GCGR mAb administration. As expected, residual pancreatic insulin content negatively correlated with the dose of STZ ([Figure 5C](#fig5){ref-type="fig"}). We thus observed beneficial effects of glucagon signaling inhibition only in diabetic mice that had retained a relatively higher pancreatic insulin after STZ-mediated β-cell loss. Strikingly, the impact of glucagon signaling inhibition on the glycemia of diabetic mice was dependent on very small measurable differences in residual pancreatic insulin, as seen after 175 and 225 mg/kg STZ (respectively 1.79% and 0.45% of the pancreatic insulin content of non-ablated controls). As seen in *Gcgr^-/-^* animals, anti-GCGR mAb administration resulted in a lower expression of hepatic Pepck ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In addition, the highest STZ dose triggered a stronger glucokinase downregulation than the 175 mg/kg dose in mAb-treated mice.10.7554/eLife.13828.015Figure 5.Anti-GCGR mAb treatment does not normalize hyperglycemia after efficient STZ-mediated β-cell ablation.(**A**) Random-fed glycemia in C57BL/6 males treated with STZ (single injection at day 0: 175 or 225 mg/kg) and/or anti-GCGR mAb (osmotic pump, days 6 to 14; N=3--6). (**B**) Area under the glycemia curves during mAb treatment. (**C**) Pancreatic insulin content. \*p\<0.05; \*\*p\<0.01; Mann Whitney *U* test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.015](10.7554/eLife.13828.015)10.7554/eLife.13828.016Figure 5---figure supplement 1.Hepatic Pepck and Glucokinase expression after STZ and/or anti-GCGR mAb treatment.Liver Pepck (left) and Glucokinase (right) mRNA levels in mice treated with STZ (single injection at day 0: 175 or 225 mg/kg) and/or anti-GCGR mAb (osmotic pump, days 6 to 14) relative to those of untreated *Gcgr^+/-^* mice (N=4--7). \*p\<0.05; \*\*p\<0.01; Mann-Whitney *U* test. Only groups that exhibited a \> twofold regulation as compared to controls (dashed lines) were tested.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.016](10.7554/eLife.13828.016)

Collectively, our findings support the notion that, regardless the method of β-cell ablation (STZ or DT), the beneficial effects of inhibiting glucagon action, either genetically or pharmacologically, rely upon residual insulin action.

Induction of insulin production in α-cells after β-cell ablation also occurs in absence of glucagon signaling {#s2-5}
-------------------------------------------------------------------------------------------------------------

We have previously shown that massive β-cell ablation triggers insulin expression in a small fraction of the α-cell population, with the appearance of glucagon/insulin bihormonal cells ([@bib40]). We report above that in such a situation of near-total β-cell loss, lack of glucagon action fails to normalize glycemia. We then assessed whether the α-cell expansion triggered by glucagon signaling inhibition could have a beneficial effect on α-cell reprogramming. One month after DT-mediated β-cell ablation, we observed bihormonal cells in *RIP-DTR;Gcgr^+/+^* and *RIP-DTR;Gcgr^-/-^* mice ([Figure 6A](#fig6){ref-type="fig"}). Because *RIP-DTR;Gcgr^-/-^* animals have α-cell hyperplasia ([@bib12]; [@bib25]) and the number of bihormonal cells was proportional to the number of α-cells in both groups ([Figure 6B](#fig6){ref-type="fig"}), we observed a significant increase in the absolute number of bihormonal cells in *RIP-DTR;Gcgr^-/-^* mice ([Figure 6C](#fig6){ref-type="fig"}). Consistent with these observations, they had a higher pancreatic insulin content ([Figure 6D](#fig6){ref-type="fig"}). These results indicate that there is an increased number of α-cells engaged into reprogramming in mice lacking glucagon signaling. We also observed the appearance of bihormonal cells in DT-treated adult *RIP-DTR* mice undergoing anti-GCGR mAb treatment ([Figure 6E--F](#fig6){ref-type="fig"}). We confirmed the α-cell origin of these newly formed bihormonal cells using a previously described tetracycline-activated system, which allows the specific and efficient doxycycline (DOX)-dependent irreversible tracing of α-cells with YFP ([Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}) ([@bib40]). One month after DT injection in *Gcgr^-/-^* mice, we observed that a significant fraction of insulin-producing cells were also YFP-positive and therefore derived from cells that had previously expressed glucagon ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). We confirmed these observations in animals in which conditional GCGR inhibition was applied after DT-mediated β-cell ablation ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}).10.7554/eLife.13828.017Figure 6.Absence of glucagon signaling does not block the appearance of new glucagon-insulin bihormonal cells after β-cell ablation.(**A**) Islet sections exhibiting glucagon-insulin co-expressing cells (arrowheads) from *RIP-DTR;Gcgr^+/+^* and *RIP-DTR;Gcgr^-/-^* females (1 m after DT). Scale bars: 20 μm. (**B-D**) Percentage of glucagon^+^ cells that co-express insulin (**B**), bihormonal cells per islet section (**C**), and pancreatic insulin content (**D**) in *RIP-DTR;Gcgr^+/+^* and *RIP-DTR;Gcgr^-/-^* females (1 m after DT, N=5--6). (**E-F**) Percentage of glucagon^+^ cells that co-express insulin (**E**), and bihormonal cells per islet section (**F**) in vehicle- or anti-GCGR mAb- treated *RIP-DTR* males (2 weeks after DT, N=3). \*p\<0.05; Mann-Whitney *U* test.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.017](10.7554/eLife.13828.017)10.7554/eLife.13828.018Figure 6---figure supplement 1.Newly formed bihormonal cells in *Gcgr^-/-^* mice are reprogrammed α-cells.(**A**) Transgenes required to irreversibly lineage-trace pancreatic α-cells with YFP before β-cell ablation. Inverted triangles represent loxP sites. (**B**) Experimental design. Upon DOX administration, the transgenic rtTA protein expressed in α-cells binds to the TetO promoter and activates Cre expression, which in turn recombines the STOP sequence in the R26-YFP transgene, leading to irreversible YFP expression. **[C]{.ul}** and **[D]{.ul}**: Example of YFP-traced cells that co-express insulin, as observed after β-cell ablation in a *RIP-DTR;Gcg-rtTA;TeTO-Cre;R26-YFP;Gcgr^-/-^* female (**C**) or in an anti-GCGR mAb-treated *RIP-DTR;Gcg-rtTA;TetO-Cre;R26-YFP* male (**D**). Higher magnification of the dotted areas is shown on the right side of panels **C** and **D**. YFP was detected using an anti-GFP antibody. Scale bars: 20 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.13828.018](10.7554/eLife.13828.018)

Together, these findings indicate that although glucagon signaling blockade does not prevent hyperglycemia in diabetic mice that exhibit extreme insulin deficiency, it results in enhanced formation of new insulin-producing cells by increasing the absolute number of converting α-cells.

Discussion {#s3}
==========

Glucagon receptor inhibition decreases hyperglycemia in various animal models of diabetes ([@bib14]; [@bib19]; [@bib2]; [@bib35]; [@bib28]; [@bib36]), as well as in patients with type 2 diabetes ([@bib21]). The extent of these benefits remains however disputed in situations where the β-cell population is nearly completely depleted, as in long-standing type 1 diabetes ([@bib48]; [@bib26]). Previous studies have shown that STZ-mediated β-cell ablation does not induce diabetes in the *Gcgr^-/-^* mouse model ([@bib7]; [@bib22]; [@bib23]), giving rise to the hypothesis that mice cannot develop hyperglycemia in absence of glucagon action ([@bib44]). Here, we show that *Gcgr^-/-^* and anti-GCGR mAb-treated animals develop severe hyperglycemia after massive DT-mediated β-cell ablation ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Our results suggest that the disparity in blood glucose levels observed between STZ- and DT-treated *Gcgr^-/-^* animals originate from a difference in β-cell destruction efficiency ([Figure 3](#fig3){ref-type="fig"}).

Recent studies reached conflicting conclusions regarding the beneficial effect of glucagon signaling blockade in severely diabetic mice: Wang et al reported that anti-GCGR mAb treatment was sufficient to normalize glycemia of STZ-treated BALB/c animals ([@bib49]), whereas Steenberg et al did not observe improvements in glucose tolerance after GCGR antagonism or glucagon immunoneutralisation in C57BL/6 mice ([@bib38]). These discrepancies may be explained by differences in completeness of β-cell ablation linked to the protocol of injection (single high dose versus multiple low doses) and/or to strain-dependent sensitivity; it was indeed reported that BALB/c mice are less sensitive to STZ than C57BL/6 animals ([@bib4]; [@bib16]). Here, we injected C57BL/6 mice with two different high doses of STZ that triggered a severe hyperglycemia; after anti-GCGR mAb treatment, however, we observed a decrease in glycemia only in animals treated with the lowest STZ dose. These results indicate that a small difference in pancreatic insulin, such as that observed after 175 and 225 mg/kg STZ, can cause a major difference in glycemia in animals lacking glucagon signaling, thereby highlighting the importance of residual insulin action and providing a potential explanation for discrepancies between previous studies ([Figure 5](#fig5){ref-type="fig"}). Remarkably, STZ-treated *Gcgr^-/-^* mice became hyperglycemic upon S961-mediated insulin receptor antagonism, illustrating the requirement of residual insulin action for maintenance of normoglycemia in these animals ([Figure 4](#fig4){ref-type="fig"}). Collectively, these findings demonstrate that a total absence of glucagon action is not sufficient to prevent hyperglycemia in case of severe insulin deficiency.

Although *Gcgr^-/-^* mice developed diabetes upon massive β-cell ablation, lack of glucagon action reduced or normalized glycemia in conditions of less severe insulin deficiency. In particular we observed that i) anti-GCGR mAb administration reduced hyperglycemia in C57BL/6 mice treated with the lowest STZ dose ([Figure 5](#fig5){ref-type="fig"}) and ii) S961 treatment caused a less severe increase in glycemia in *Gcgr^-/-^* than in *Gcgr^+/-^* animals ([Figure 4A](#fig4){ref-type="fig"}). Our data on hepatic expression of Pepck and Gck, two rate-limiting enzymes of gluconeogenesis and glycolysis, respectively, suggest that lack of glucagon signaling counterbalances the effects of insulin insufficiency after STZ or S961. This would prevent, or limit, the rise in net hepatic glucose output by decreasing gluconeogenesis and glycogenolysis, and by increasing glycolysis and glycogenesis. Absence of glucagon action is however not sufficient to compensate severe insulin deficiency after DT, as reflected by Gck downregulation and reduced hepatic glycogen content, thereby contributing to the elevation of blood glucose. Interestingly, the mRNA levels of FoxO1 target genes in skeletal muscle were strongly upregulated, reflecting insulin signaling insufficiency, after DT and STZ+S961, the two conditions that led to hyperglycemia ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). In addition, gonadal adipose tissue was markedly depleted in experimental conditions leading to hyperglycemia (in *Gcgr^-/-^* mice after STZ+S691 and DT; in *Gcgr^+/-^* mice after STZ and DT; not shown). Together, these findings provide new insights into the mechanisms by which lack of glucagon signaling protects against elevated blood glucose levels in situations of insulin insufficiency. Recent studies have shown that protection against STZ-mediated hyperglycemia also rely on the high levels of circulating glucagon-like peptide-1 (GLP-1) in *Gcgr^-/-^* animals ([@bib15]; [@bib1]; [@bib20]; [@bib29]). Yet, these high levels of GLP-1 combined with a lack of glucagon action were insufficient to maintain normoglycemia after near-total β-cell loss.

Finally, we report here that lack of glucagon signaling does not compromise the ability of α-cells to convert to insulin production after DT-mediated near-total β-cell loss. Indeed, YFP-traced α-cells become glucagon/insulin bihormonal cells after DT in *RIP-DTR;Gcgr^-/-^* mice and in animals treated with the anti-GCGR antibody ([Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The proportion of α-cells co-expressing insulin after DT is comparable between mice with either intact, reduced or absent glucagon signaling, indicating that glucagon does not play an essential role in the α-to-β transdifferentiation process. Interestingly, because glucagon signaling inhibition leads to a compensatory α-cell hyperplasia ([@bib11]; [@bib12]; [@bib25]), the absolute number of newly formed insulin-producing cells through α-cell conversion was augmented in *RIP-DTR;Gcgr^-/-^* mice. As previously described in adult mice ([@bib6]), we also observed the δ-to-β conversion in β-cell-ablated *RIP-DTR;Gcgr^-/-^* mice (not shown).

In conclusion, although inhibition of glucagon action alone is insufficient to prevent diabetes in conditions of near-total insulin deficiency, it is beneficial when residual insulin action persists, as in STZ-treated *Gcgr^-/-^* animals. Combination of glucagon inhibition with insulin therapy may however increase the risk of hypoglycemia. We encountered this problem when using subcutaneous insulin pellets in DT-treated *RIP-DTR;Gcgr^-/-^* mice: they became hypoglycemic and died likely as a consequence of the constitutive insulin release from the pellets, which could not be compensated by glucagon action. Our findings suggest that diabetes therapy through glucagon suppression would be unsafe if exogenous insulin has to be supplemented, but may be beneficial in patients with sufficient residual insulin action. In case of near-total insulin deficiency, transient glucagon receptor blockade could also serve as a means to increase the α-cell mass before triggering insulin production in these cells, a strategy that might be envisioned as a novel therapy to treat diabetes.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

*Gcgr^-/-^* ([@bib12]), *RIP-DTR* (Rat insulin promoter - diphtheria toxin receptor) ([@bib40]), *Gcg-rtTA* (Glucagon promoter - reverse tetracycline transactivator) ([@bib40]), *TetO-Cre* (Tetracycline operator - Cre recombinase) ([@bib31]), and *R26-YFP* (Rosa26 promoter - yellow fluorescent protein) ([@bib37]) mice were described previously and bred on a C57BL/6-enriched mixed genetic background. As pups born from *Gcgr^-/-^* mothers die perinatally ([@bib46]), *Gcgr^+/-^* females were used for breeding. C57BL/6 mice were purchased from Janvier Labs (France). All mice used in this study were adult (10--20 week old) males or females. They were housed and treated in accordance with the guidelines and regulations of the Direction Générale de la Santé, state of Geneva. Blood glucose was measured from tail blood using a handheld glucometer (detection range: 0.6 to 33.3 mM, values exceeding 33.3 mM were artificially set to 34 mM).

Diphtheria toxin (DT), Streptozotocin (STZ), and Doxycycline (DOX) treatments {#s4-2}
-----------------------------------------------------------------------------

For β-cell ablation in *RIP-DTR* mice, DT (D0564, Sigma, St. Louis, MO) was injected i.p. in 3 injections of 125 ng each, at days 0, 3, and 4. STZ (S0130, Sigma) was used as an alternative method of β-cell ablation. It was freshly diluted in citrate buffer and administered in 5-h fasted mice. Two different protocols were used depending on the genetic background: i) *Gcgr^+/-^* and *Gcgr^-/-^* mice: two i.p. injections of 200 and 150 mg/kg, one week apart; ii) C57BL/6 mice: single i.p. injection (175 or 225 mg/kg). For inducible α-cell labeling in *Gcg-rtTA;TetO-Cre;R26-YFP* mice, DOX (D9891, Sigma) was added to drinking water (1 mg/ml) for 2 weeks followed by at least 2 weeks of clearance before DT injection.

Anti-GCGR mAb {#s4-3}
-------------

Anti-GCGR monoclonal antibody A-9 was generated at Eli Lilly and Company (Yan H, Hu S-FS, Boone TC, Lindberg RA, inventors; Amgen Inc., assignee. Compositions and methods relating to glucagon receptor antibodies. United States patent US 8158759 B2, 2012 Apr 17). It was delivered either via i.p. injections, thrice weekly (9 mg/kg per injection), or using a s.c. implanted osmotic pump (model 2002, Alzet, Cupertino, CA) containing 11 mg/ml of anti-GCGR mAb in PBS (estimated delivery rate: 5.5 μg/h for 2 weeks).

S961 {#s4-4}
----

The insulin receptor inhibitor S961 was a kind gift of Lauge Schäffer (Novo Nordisk, Denmark) ([@bib33]). Mice were implanted s.c. with an osmotic pump (model 1007D, Alzet) loaded with 40 nmol S961 (estimated delivery rate: 0.25 nmol/h for 1 week).

Insulin {#s4-5}
-------

Long-acting insulin detemir (Levemir, Novo Nordisk) was freshly diluted in NaCl 0.9% and injected s.c. twice per day (1.7 U/kg in the morning, 3.3 U/kg in the evening). Insulin pellets (LinShin Canada Inc., Canada) were implanted s.c.

Intraperitoneal glucose tolerance test (ipGTT) and insulin tolerance test (ITT) {#s4-6}
-------------------------------------------------------------------------------

For the ipGTT, mice were fasted overnight (15 hr) and then injected i.p. with 2 mg/kg *D*-glucose. For the ITT, mice were fasted for 5 hr and injected i.p. with 0.7 U/kg insulin (Humalog, Eli Lilly).

Immunofluorescence {#s4-7}
------------------

Following euthanasia, collected pancreata were processed as described ([@bib10]). Paraffin and cryostat sections were 5 and 10 μm-thick, respectively. Primary antibodies: guinea pig anti-insulin (1:400, Dako, Denmark), mouse anti-glucagon (1:250 to 1:1000, Sigma), and rabbit anti-GFP (1:200, Molecular Probes Inc., Eugene, OR). Secondary antibodies were coupled to Alexa Fluor dyes 488, 568, or 647 (1:500, Molecular Probes Inc.); or to FITC, Cy3, or Cy5 (1:500, Jackson ImmunoResearch, West Grove, PA). Images were acquired on a confocal microscope (TCS SPE, Leica Microsystems, Germany). For cell mass measurement, 8 to 12 equally spaced sections per pancreas were imaged on a Leica M205 FA stereo microscope. Islets were manually selected using ImageJ (NIH) and thresholding was applied to measure the insulin- and glucagon-positive areas.

RNA extraction and RT-qPCR {#s4-8}
--------------------------

After dissection, liver and skeletal muscle (gastrocnemius) were immediately stored in RNAlater (Sigma). Tissues were homogenized with a Polytron and total RNA was extracted with the Qiagen (Germany) RNeasy mini kit (standard kit for liver, fibrous tissue kit for muscle). Reverse transcription was performed using the Qiagen QuantiTect RT kit. qPCR reactions and analyses were performed as described ([@bib40]); each sample was run in triplicate. For normalization, eight housekeeping genes were tested and the three more stable across our experimental conditions were defined using geNorm ([@bib45]): *β-Glucuronidase (Gusb), Glyceraldehyde-3-phosphate dehydrogenase (Gapdh*), and *Non-POU-domain-containing, octamer binding protein (Nono*) for liver; *β-actin (Actb), Gapdh*, and *Gusb* for skeletal muscle. Primer sequences are indicated in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

Hormone and glycogen measurements {#s4-9}
---------------------------------

Protein extracts from total pancreas were prepared as described ([@bib39]). Blood samples were collected in EDTA-coated tubes and plasma was separated by centrifugation. Insulin and glucagon concentrations were measured using Ultrasensitive Mouse Insulin and Glucagon ELISA kits (Mercodia, Sweden), respectively. Glycogen concentration was measured from the supernatatant of homogenized liver tissue using a glycogen asssay kit (Sigma).

Immunoblotting {#s4-10}
--------------

Liver samples were lyzed in radioimmumoprecipitation (RIPA) buffer with protease inhibitors (Thermo Fisher Scientific, Waltham, MA). Protein concentration was measured using a BCA assay (Thermo Fisher Scientific). Proteins were resolved on a TruPAGE gel (Sigma) and transferred to a PVDF membrane. The membrane was blocked in Tris-buffered saline with 0.1% Tween containing 5% bovine serum albumin. Primary antibodies were rabbit anti-PEPCK (1:1500, Abcam, UK) and mouse anti-tubulin (1:2500), both incubated overnight at 4°C; secondary antibodies were horseradish peroxidase-conjugated anti-rabbit (1:5000) and anti-mouse (1:5000). Proteins were detected using ECL plus substrate (Thermo Fisher Scientific) and images were acquired on a LAS-4000 imager (Fujifilm, Japan).

Statistical analyses {#s4-11}
--------------------

Data are presented as mean ± SEM. *P* values were calculated with GraphPad Prism 6 (GraphPad Software, La Jolla, CA). The following statistical tests were applied: unpaired, two-tailed, Mann-Whitney *U* test for two sample comparisons; one- or two-way ANOVA with post hoc Bonferroni correction for multiple comparisons; Log-rank (Mantel-Cox) test for survival analyses.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Guy Rutter as the Reviewing Editor and Fiona Watt as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The following individuals involved in review of your submission have agreed to reveal their identity: Gordon Weir (peer reviewer).

Summary:

The manuscript is timely since the paper from Unger et al. (2011), which the present manuscript challenges, suggested that suppression of glucagon action alone (in the absence of insulin signalling) is sufficient to prevent diabetes, giving strong support to the \"bihormonal\" model of diabetes induction. This work from Herrera and colleagues demonstrates (though doesn\'t quite prove) that the model used by Unger and colleagues was likely to involve persistent insulin production and signalling, rather weakening this assertion. The other observation here -- that α cells can still convert to β cells in the absence of glucagon signalling -- is also interesting, but is arguably tangential to the main thrust of the paper.

The paper is well written and of sound scientific quality. The subject is interesting and valuable for a broad range of researchers. Importantly, it clarifies an existing puzzle in the literature and has therapeutic implications.

In summary, this is an important paper for the field. However, there are important suggestions for revision, including discussion of recent relevant literature (notably the recent report by JJ Holst and colleagues in Diabetologia), reanalysis of β and α cell mass data and/or possible further experimentation to provide adequate quantification of these parameters.

Essential revisions:

1\) The ablation of β cells by STZ was certainly incomplete as is often the case. It is not easy to determine the perfect dose, but more complete ablation might have been achieved with a higher dose and a longer fast, which would have lowered the glucose level and enhanced the STZ uptake by the β cells. In any case, it would be helpful to explain in the Introduction that STZ treatment does not always destroy all the β-cells in the pancreas. It depends on the dose, mouse strain, etc.

In particular, the authors need to explain how they chose their STZ concentrations. Even the lowest dosage they used (175mg/kg) is almost twice as high that as in the cited papers (100mg/kg). This lower dose likely explains why ablation of glucagon signalling was beneficial in previous studies, and this should be discussed. In any case, the STZ concentration used should be stated in the legend of each figure, given that very small changes can affect β-cell loss and thus the effect of glucagon signalling ablation. (e.g. in [Figures 3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"})

2\) Related to this, the pancreatic insulin content of the STZ group was 21% of normal. If the glucose was high there might have been degranulation, so is it possible that the actual β cell mass was even higher, that is over 21% of normal.

3\) Regarding the pancreatic insulin content. If a normal mouse pancreas weighs 100 mg, the insulin content would be 100 ng x 100 mg = 10,000 ng or 10 μg per mouse panaceas, which is about what others get. In [Figure 6](#fig6){ref-type="fig"}, after the DT, the insulin content of the pancreases is 10 ng/pancreas, which show the remarkable efficiency of DT ablation. In this figure please indicate the significance level for the asterisks shown.

4\) There is great interest in the mass of β cells required to prevent diabetes in both mice and humans. The current paper does not have true mass measurements. It is difficult to make sense of pancreatic insulin content and number of β cells per islet section. The paper would be stronger if mass were measured in some groups of the mice used in this study. In particular, in would be of great interest to know the β cell mass required to prevent diabetes with and without glucagon receptors either knocked out or blocked. Related to this, it would also be of value to determine the mass of α cells and the mass of insulin/glucagon double positive cells. This gets at the important question of understanding of how many β cells can be generated from α cells and whether they make a meaningful contribution to insulin secretion.

5\) A recent paper in Diabetologia (vol 59, p363) from Holst and colleagues comes to a similar conclusion although with a somewhat different approach. Glucagon immunoneutralisation was tested, with the same results as reported here. However, glucagon signalling was also disrupted by ablation of glucagon-secreting α cells or using a glucagon receptor antibody. This paper should be discussed. Even older work from the same laboratory (PMID: 7851693) is also relevant here and should be cited.

6\) Although the authors show measures of blood-glucose levels which is the final output of interest, the mechanistic approach in the attempt to explain the reasons for why insulin is needed is lacking. The measurements on the important liver enzymes is limited and only mRNA-levels are evaluated. At least the key glucogenic protein PEPCK should also be measured on protein level.

7\) In addition, gene expression levels of other key lever genes could be measured (e.g. G6Pc, Fbp1 and Pcx) to get a more detailed picture on the liver function.

10.7554/eLife.13828.021

Author response

Essential revisions:

1\) The ablation of β cells by STZ was certainly incomplete as is often the case. It is not easy to determine the perfect dose, but more complete ablation might have been achieved with a higher dose and a longer fast, which would have lowered the glucose level and enhanced the STZ uptake by the β cells. In any case, it would be helpful to explain in the Introduction that STZ treatment does not always destroy all the β-cells in the pancreas. It depends on the dose, mouse strain, etc.

STZ-mediated β-cell ablation was indeed incomplete, as clearly shown by our data in [Figure 3](#fig3){ref-type="fig"}. Although altering the STZ injection protocol may have slightly increased the ablation efficiency, it is very unlikely that we could have achieved a near-total β-cell destruction in glucagon receptor knockout (*Gcgr-/-*) animals, which are less sensitive to this chemical than their *Gcgr+/+* or *Gcgr+/-* counterparts. This is precisely why we opted for alternative methods: i) the more efficient DT-mediated ablation in *RIP-DTR;Gcgr-/-* mice; ii) additional insulin signaling inhibition with S961 after STZ treatment; and iii) glucagon signaling blockade in STZ-treated C57BL/6 mice.

We have added a sentence in the Introduction to indicate that the efficiency of STZ-mediated β-cell ablation depends on the administration protocol and mouse strain.

In particular, the authors need to explain how they chose their STZ concentrations. Even the lowest dosage they used (175mg/kg) is almost twice as high that as in the cited papers (100mg/kg). This lower dose likely explains why ablation of glucagon signalling was beneficial in previous studies, and this should be discussed. In any case, the STZ concentration used should be stated in the legend of each figure, given that very small changes can affect β-cell loss and thus the effect of glucagon signalling ablation. (e.g. in [Figures 3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"})

We performed pilot experiments to determine optimal STZ dosages (maximization of β-cell ablation with low mortality). Please note that in the cited papers, 100 mg/kg STZ was administered i.v., whereas we used a higher dose injected i.p.

We used two different protocols of STZ administration, depending on the genetic background:

a\) *Gcgr+/-* and *Gcgr-/-* mice ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}): first injection of 200 mg/kg followed one week later by a second injection of 150 mg/kg.

b\) C57BL/6 mice ([Figure 5](#fig5){ref-type="fig"}): single injection of either 175 mg/kg or 225 mg/kg.

We added the STZ administration protocol to the legend of each figure and clarified the STZ paragraph in the Materials and methods section.

Regarding the beneficial effect of glucagon signaling, we reach the same outcome as the mentioned papers, that is: *Gcgr-/-* mice remain normoglycemic after STZ treatment. Here, we report that if a more efficient method of β-cell ablation (DT-mediated) or additional insuling signaling blockade (STZ+S961) are applied, *Gcgr-/-* animals become severely diabetic despite the complete absence of glucagon signaling.

2\) Related to this, the pancreatic insulin content of the STZ group was 21% of normal. If the glucose was high there might have been degranulation, so is it possible that the actual β cell mass was even higher, that is over 21% of normal.

As reported in previous papers and confirmed by us in this manuscript (see [Figure 4A](#fig4){ref-type="fig"}, purple inverted triangles), *Gcgr-/-* mice remain normoglycemic after treatment with STZ.

To assess degranulation, we stained islets from untreated or STZ-treated *Gcgr-/-* mice for Nkx6.1 and insulin. As shown in the pictures below, over 90% of Nkx6.1-positive cells still co-expressed insulin after STZ, arguing against a significant β-cell degranulation in these animals.

3\) Regarding the pancreatic insulin content. If a normal mouse pancreas weighs 100 mg, the insulin content would be 100 ng x 100 mg = 10,000 ng or 10 μg per mouse panaceas, which is about what others get. In [Figure 6](#fig6){ref-type="fig"}, after the DT, the insulin content of the pancreases is 10 ng/pancreas, which show the remarkable efficiency of DT ablation. In this figure please indicate the significance level for the asterisks shown.

DT-mediated β-cell ablation is very efficient indeed. Our values for pancreatic insulin content are consistent with the estimates of this reviewer: 150 ng/mg in untreated and 0.1 ng/mg in DT-treated *RIP-DTR;Gcgr+/-* mice (see [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, new data provided in the revised manuscript).

We have added the requested P values directly on the graphs ([Figure 6C: P](#fig6){ref-type="fig"}=0.022 and [Figure 6D: P](#fig6){ref-type="fig"}=0.015).

4\) There is great interest in the mass of β cells required to prevent diabetes in both mice and humans. The current paper does not have true mass measurements. It is difficult to make sense of pancreatic insulin content and number of β cells per islet section. The paper would be stronger if mass were measured in some groups of the mice used in this study. In particular, in would be of great interest to know the β cell mass required to prevent diabetes with and without glucagon receptors either knocked out or blocked. Related to this, it would also be of value to determine the mass of α cells and the mass of insulin/glucagon double positive cells. This gets at the important question of understanding of how many β cells can be generated from α cells and whether they make a meaningful contribution to insulin secretion.

We measured the β- and α-cell masses in untreated, STZ- and DT-treated RIP-*DTR;Gcgr+/+* and *RIP-DTR;Gcgr-/-* mice. These new data were added to the [Figure 3](#fig3){ref-type="fig"} in the revised manuscript ([Figure 3B](#fig3){ref-type="fig"}, in replacement of previous panel 3B, and [Figure 3---figure supplements 1B](#fig3s1){ref-type="fig"} and [2A](#fig3s2){ref-type="fig"}). Of note, we find a good correlation between the β-cell mass and the pancreatic insulin content.

The question of the β-cell mass required to prevent diabetes in the presence or absence of glucagon signaling is very interesting. However, differences in sensitivity to STZ between *Gcgr+/-* and *Gcgr-/-* mice makes it difficult to obtain a similar ablation efficiency in these two genotypes. A large cohort of mice treated with different doses of STZ combined or not with anti-GCGR mAb administration would be required to accurately evaluate the minimal β-cell mass needed to prevent diabetes in situations of normal or blocked glucagon signaling. In this study, we already observe a beneficial effect of glucagon receptor blockade therapy on the glycemia of STZ-treated C57BL/6 mice in presence of a tiny amount of residual insulin (1.79% of pancreatic insulin content, [Figure 5](#fig5){ref-type="fig"}).

The bihormonal cell mass is difficult to measure, but we can calculate it indirectly. After DT in *RIP-DTR;Gcgr-/-* animals, we find that the average α-cell mass is 4.92 mg ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) and that 0.73% of glucagon-positive cells make insulin ([Figure 6B](#fig6){ref-type="fig"}). Thus, we can estimate the bihormonal cell mass to be around 36 μg, that is less than 3% of the β-cell mass in untreated mice. Even if these cells were secreting insulin like β-cells, this amount would be insufficient to prevent hyperglycemia. Rescuing insulin deficiency by conversion of α-cells will therefore require additional interventions to promote α-cell reprogramming. This however falls outside of the scope of this manuscript.

5\) A recent paper in Diabetologia (vol 59, p363) from Holst and colleagues comes to a similar conclusion although with a somewhat different approach. Glucagon immunoneutralisation was tested, with the same results as reported here. However, glucagon signalling was also disrupted by ablation of glucagon-secreting α cells or using a glucagon receptor antibody. This paper should be discussed. Even older work from the same laboratory (PMID: 7851693) is also relevant here and should be cited.

We have modified the Discussion to include this very recent publication.

In agreement with this study, we also reported that α-cell ablation does not improve glycemic control after massive DT-mediated α- and β-cell co-ablation in *RIP-DTR;Glucagon-DTR* double transgenic mice (Thorel et al., Diabetes, 2011).

6\) Although the authors show measures of blood-glucose levels which is the final output of interest, the mechanistic approach in the attempt to explain the reasons for why insulin is needed is lacking. The measurements on the important liver enzymes is limited and only mRNA-levels are evaluated. At least the key glucogenic protein PEPCK should also be measured on protein level.

We performed a western blot analysis to measure Pepck expression at the protein level in untreated and DT-treated *RIP-DTR;Gcgr+/-* and *RIP-DTR;Gcgr-/-* mice. This data was added to the revised manuscript ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Consistent with mRNA data, PEPCK protein expression is higher in DT-treated animals.

7\) In addition, gene expression levels of other key lever genes could be measured (e.g. G6Pc, Fbp1 and Pcx) to get a more detailed picture on the liver function.

We have chosen to show the expression levels of Pepck and Gck because the expression of these genes is known to be regulated by both glucagon and insulin at the transcriptional level.

As requested, we measured the liver expression of G6pc, Fbp1, Pcx, and Pklr in our different experimental conditions. G6pc, a key enzyme in gluconeogenesis and glycogenolysis, displayed a similar regulation as that of Pepck consistent with increased glucose mobilization after DT.

The other genes displayed a subtler regulation in response to alterations of insulin (Pcx) or glucagon (Pklr, Fbp1) action. As it is more difficult to draw conclusions from these small variations, we have not included these data in the revised manuscript.

Altogether, the results provided in [Figure 4](#fig4){ref-type="fig"} show that after DT in *Gcgr-/-* animals: i) the expression of key gluconeogenic genes in the liver is increased (Pepck and G6pc at the transcript level, PEPCK at the protein level), ii) the liver glycogen content is reduced, and iii) the expression of insulin-sensitive genes, such as Irs2, is increased in skeletal muscle. Combined, these data support the hypothesis that DT treatment causes a severe insulin deficiency that cannot be compensated by the absence of glucagon signaling in these animals. This likely leads to a higher glucose mobilization and/or a lower glucose uptake resulting in hyperglycemia and diabetes.
